Reaffirmed: Shire (NASDAQ:SHPG) Hold Rating Maintained by Analysts at Piper Jaffray; $154.0 Target in Place

April 23, 2018 - By Vivian Currie

Shire plc (NASDAQ:SHPG) Logo

Shire (NASDAQ:SHPG) Rating Reaffirmed

In an analyst note revealed to investors and clients this morning, Piper Jaffray reaffirmed their Hold rating on Shire (NASDAQ:SHPG) shares. The price target gives a possible downside of -4.35 % from company’s current price.

Shire plc (NASDAQ:SHPG) Ratings Coverage

Among 14 analysts covering Shire (NASDAQ:SHPG), 11 have Buy rating, 0 Sell and 3 Hold. Therefore 79% are positive. Shire has $260.0 highest and $150.0 lowest target. $201’s average target is 24.84% above currents $161 stock price. Shire had 24 analyst reports since October 26, 2017 according to SRatingsIntel. As per Thursday, February 15, the company rating was maintained by Jefferies. The company was maintained on Friday, January 5 by Cowen & Co. Piper Jaffray maintained Shire plc (NASDAQ:SHPG) rating on Wednesday, February 14. Piper Jaffray has “Hold” rating and $150.0 target. The firm earned “Hold” rating on Wednesday, December 20 by Liberum Capital. The stock has “Buy” rating by Jefferies on Wednesday, December 20. J.P. Morgan downgraded Shire plc (NASDAQ:SHPG) rating on Monday, February 19. J.P. Morgan has “Hold” rating and $150.0 target. RBC Capital Markets maintained Shire plc (NASDAQ:SHPG) rating on Monday, February 5. RBC Capital Markets has “Buy” rating and $192.0 target. The firm earned “Buy” rating on Friday, February 16 by Susquehanna. Susquehanna maintained the stock with “Buy” rating in Wednesday, November 15 report. As per Wednesday, February 14, the company rating was upgraded by Bernstein.

The stock decreased 2.05% or $3.37 during the last trading session, reaching $161. About 1.11 million shares traded. Shire plc (NASDAQ:SHPG) has declined 27.67% since April 23, 2017 and is downtrending. It has underperformed by 39.22% the S&P500.

Analysts await Shire plc (NASDAQ:SHPG) to report earnings on April, 26 before the open. They expect $3.58 earnings per share, down 1.38 % or $0.05 from last year’s $3.63 per share. SHPG’s profit will be $1.07 billion for 11.24 P/E if the $3.58 EPS becomes a reality. After $3.98 actual earnings per share reported by Shire plc for the previous quarter, Wall Street now forecasts -10.05 % negative EPS growth.

Shire plc, a biotechnology company, focused on serving people with rare diseases and other specialized conditions worldwide. The company has market cap of $48.12 billion. The firm offers products in therapeutic areas, including hematology, genetic diseases, neuroscience, immunology, internal medicine, ophthalmology, and oncology. It has a 11.47 P/E ratio. The Company’s marketed products include ADVATE and ADYNOVATE/ADYNOVI for hemophilia A; RIXUBIS to treat hemophilia B; VONVENDI for the treatment of von willebrand Disease; FEIBA to treat hemophilia A and B patients with inhibitors; CINRYZE and FIRAZYR for hereditary angioedema; ELAPRASE to treat hunter syndrome; REPLAGAL for Fabry disease; and VPRIV to treat type 1 Gaucher disease.

Shire plc (NASDAQ:SHPG) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.